Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 2/2017

11.11.2016 | Letter to the Editor

Cancer and hereditary haemorrhagic telangiectasia

verfasst von: A. E. Hosman, C. L. Shovlin

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

To examine associations between cancer incidence and hereditary haemorrhagic telangiectasia (HHT).

Methods

Two studies with contrasting conclusions were compared. The first had used a registry-based, matched-pairs approach, while the second utilised HHT family-based, survey methodology.

Results

The first manuscript captured data on cancer incidence in a total of 316,581 matched cancer patients–non-cancer controls, which included 431 HHT cases. No association was found between HHT and pooled cases of lung, breast, prostate, and colorectal cancer (adjusted OR 0.978, 95% CI [0.795, 1.204]). The second, which was powered to examine these four cancers individually, captured data from 2161 HHT cases and 2817 related controls. Fewer HHT-affected individuals had cancer (398/2161, [18.4%]) compared to 668/2817 (23.7%) related controls (p = 0.0012). Of the four most common cancers, prostate and colorectal cancer rates were equivalent, but lung cancers were significantly less frequent in HHT (adjusted OR 0.48 [0.30, 0.70], p = 0.0012), and breast cancer was more frequent (adjusted OR 1.52 [1.07, 2.14] p = 0.018).

Conclusions

The respective studies had different methodological strengths and weaknesses. Potential reasons for the discrepant conclusions include study power, particularly important to dissect specific cancers where differential contributions from HHT genotypes and environmental confounders might be predicted.
Literatur
Zurück zum Zitat Duarte CW, Murray K, Lucas FL, Fairfield K, Miller H, Brooks P, Vary CP (2014) Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomark Prev 23(1):117–125CrossRef Duarte CW, Murray K, Lucas FL, Fairfield K, Miller H, Brooks P, Vary CP (2014) Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia. Cancer Epidemiol Biomark Prev 23(1):117–125CrossRef
Zurück zum Zitat Duarte CW, Black AW, Lucas FL, Vary CP (2016) Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol (Epub ahead of print) Duarte CW, Black AW, Lucas FL, Vary CP (2016) Cancer incidence in patients with hereditary hemorrhagic telangiectasia. J Cancer Res Clin Oncol (Epub ahead of print)
Zurück zum Zitat GLOBOCAN (2008) Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. http://globocan.iarc.fr. Globocan 2012. Accessed 17 Oct 2016 GLOBOCAN (2008) Estimated cancer incidence, mortality, prevalence and disability-adjusted life years (DALYs) worldwide in 2008. http://​globocan.​iarc.​fr. Globocan 2012. Accessed 17 Oct 2016
Zurück zum Zitat Hanneman K, Faughnan ME, Prabhudesai V (2014) Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Can Assoc Radiol J 65(2):135–140CrossRefPubMed Hanneman K, Faughnan ME, Prabhudesai V (2014) Cumulative radiation dose in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Can Assoc Radiol J 65(2):135–140CrossRefPubMed
Zurück zum Zitat Hosman AE, Devlin HL, Silva BM, Shovlin CL (2013) Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 20(8):195CrossRef Hosman AE, Devlin HL, Silva BM, Shovlin CL (2013) Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 20(8):195CrossRef
Zurück zum Zitat Jelsig AM, Tørring PM, Kjeldsen AD, Qvist N, Bojesen A, Jensen UB, Andersen MK, Gerdes AM, Brusgaard K, Ousager LB (2016) JP-HHT phenotype in Danish patients with SMAD4 mutations. Clin Genet 90(1):55–62CrossRefPubMed Jelsig AM, Tørring PM, Kjeldsen AD, Qvist N, Bojesen A, Jensen UB, Andersen MK, Gerdes AM, Brusgaard K, Ousager LB (2016) JP-HHT phenotype in Danish patients with SMAD4 mutations. Clin Genet 90(1):55–62CrossRefPubMed
Zurück zum Zitat Kjeldsen AD, Vase P, Green A (1999) Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 245:31–39CrossRefPubMed Kjeldsen AD, Vase P, Green A (1999) Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 245:31–39CrossRefPubMed
Zurück zum Zitat Mollet IG, Patel D, Govani FS, Giess A, Paschalaki K, Periyasamy M, Lidington EC, Mason JC, Jones MD, Game L, Ali S, Shovlin CL (2016) Low dose iron treatments induce a DNA damage response in human endothelial cells within minutes. PLoS ONE 11(2):e0147990CrossRefPubMedPubMedCentral Mollet IG, Patel D, Govani FS, Giess A, Paschalaki K, Periyasamy M, Lidington EC, Mason JC, Jones MD, Game L, Ali S, Shovlin CL (2016) Low dose iron treatments induce a DNA damage response in human endothelial cells within minutes. PLoS ONE 11(2):e0147990CrossRefPubMedPubMedCentral
Metadaten
Titel
Cancer and hereditary haemorrhagic telangiectasia
verfasst von
A. E. Hosman
C. L. Shovlin
Publikationsdatum
11.11.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2017
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2298-x

Weitere Artikel der Ausgabe 2/2017

Journal of Cancer Research and Clinical Oncology 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.